| 초록 |
RNA interference (RNAi), mediated by small interfering RNA (siRNA), has been considered as a potential therapeutic agent for cancer owing to its ability to suppress target genes in a sequence-specific manner. However, the inherent susceptibility of siRNA to degradation by nucleases in the blood and its poor cellular uptake have been considered major challenges for the clinical use of the systemic siRNA therapy. Therefore, an effective and stable systemic siRNA delivery system should be established. 4-fluorothiophenol-deoxycholic acid-polyethylenimine conjugates could generate stable nanoparticles with thiol-siRNA. The conjugates showed significant tumor growth inhibition effect in tumor-bearing mice after systemic administration. Therefore, the synthesized conugates could be considered as a candidate carrier for systemic cancer therapy using siRNA therapeutics. |
